Drug Targeting Organ-Specific Strategies

154 5 Delivery of Drugs and Antisense Oligonunucleotides to the Proximal Tubular Cell
[107] Zhang R, Lu Z, Zhao H, Zhang X, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D, Agrawal S,
Biochem. Pharmacol. 1995, 50, 545–556.
[108] Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL, Greig MJ, Guinosso
CJ, Kornbrust D, Manoharan M, Sasmor HM, Schleich T, Tivel KL, Griffey RH, J. Pharmacol.
Exp. Ther. 1996, 277, 923–937.
[109] Agrawal S, Temsamani J, Galbraith W, Tang J, Clin. Pharmacokinet. 1995, 28, 7–16.
[110] Oberbauer R, Schreiner GF, Meyer TW, Kidney Int. 1995, 48, 1226–1232.
[111] Grindel JM, Musick TJ, Jiang Z, Roskey A, Agrawal S, Antisense Nucleic Acid Drug Dev. 1998, 8,
43–52.
[112] Maeshima Y, Kashihara N, Sugiyama H, Sekikawa T, Okamoto K, Kanao K, Morita Y, Yamasaki
Y, Makino H, Ota Z, J. Am. Soc. Nephrol. 1994, 5, 835–835.
[113] Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, Beck T, Bryan B, Cotter
FE, J. Pharmacol. Exp. Ther. 1997, 281, 420–427.
[114] Cossum PA, Truong L, Owens SR, Markham PM, Shea JP, Crooke ST, J. Pharmacol. Exp. Ther.
1993, 267, 1181–1190.
[115] Nicklin PL, Craig SJ, Phillips JA, In: Antisense Research and Application (Ed. Crooke ST), pp.
141–168. Springer Verlag, Berlin, 1998.
[116] Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA, Anticancer Drug Des. 1997, 12,
383–393.
[117] Rifai A, Brysch W, Fadden K, Clark J, Schlingensiepen KH, Am. J. Pathol. 1996, 149, 717–725.
[118] Sands H, Gorey Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL, Mol. Pharmacol.
1994, 45, 932–943.
[119] Carome MA, Kang YH, Bohen EM, Nicholson DE, Carr FE, Kiandoli LC, Brummel SE, Yuan
CM, Nephron 1997, 75, 82–87.
[120] Stein CA, Mori K, Loke SL, Subasinghe C, Cohen JS, Neckers LM, Gene 1988, 72, 333–341.
[121] Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM,
Proc. Natl Acad. Sci. USA. 1989, 86, 3474–3484.
[122] Bennett RM, Gabor GT, Morritt MJ, J. Clin. Invest. 1985, 76, 2182–2190.
[123] Rappaport J, Hanss B, Kopp JB, Copeland TD, Bruggeman LA, Coffman TM, Klotman PE, Kidney
Int. 1995, 47, 1462–1469.
[124] Hanss B, Leal-Pinto E, and Klotman PE, J. Am. Soc. Nephrol. 1994, 6, 362–362.
[125] Sawai K, Mahato RI, Oka Y, Takakura Y, Hashida M, J. Pharmacol. Exp. Ther. 1996, 279,
284–290.
[126] Agrawal S, Temsamani J, Tang JY, Proc. Natl Acad. Sci. USA 1991, 88, 7595–7599.
[127] Temsamani J, Tang JY, Padmapriya A, Kubert M, Agrawal S, Antisense Res. Dev. 1993, 3,
277–284.
[128] Temsamani J, Roskey A, Chaix C, Agrawal S, Antisense Nucleic Acid Drug Dev. 1997, 7,
159–165.
[129] Noiri E, Peresleni T, Miller F, Goligorsky MS, J. Clin. Invest. 1996, 97, 2377–2383.
[130] Oberbauer R, Schreiner GF, Biber J, Murer H, Meyer TW, Proc. Natl Acad. Sci. USA 1996, 93,
4903–4906.
[131] Wang ZQ, Felder RA, Carey RM, Hypertension 1999, 33, 504–510.
[132] Chen W, Bennett CF, Wang ME, Dragun D, Tian L, Stecker K, Clark JH, Kahan BD, Stepkowski
SM, Transplantation 1999, 68, 880–887.
[133] Cheng QL, Chen XM, Li F, Lin HL, Ye YZ, Fu B, Kidney Int. 2000, 57, 183–190.
[134] Okada H, Moriwaki K, Kalluri R, Takenaka T, Imai H, Ban S, Takahama M, Suzuki H, Am. J.
Physiol. 2000, 278, F110–F121.
[135] Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN, Am. J. Physiol. 2000, 278, F628–F634.
[136] Weir MR, Am. J. Hypertens. 1999, 12, 195S–203S.
[137] Briggs WA, Gimenez LF, Samaniego-Picota M, Choi MJ, Nadasdy T, Eustace J, Scheel PJ, Jr,
J. Clin. Pharmacol. 2000, 40, 115–123.
[138] Gruber SA, Immunol. Rev. 1992, 129, 5–30.
[139] Motzer RJ, Russo P, J. Urol. 2000, 163, 408–417.
[140] Edwards RM, Stack EJ, Trizna W, J. Pharmacol. Exp. Ther. 1999, 290, 38–42.
[141] Muller-Berger S, Nesterov VV, Fromter E, Pflugers Arch. 1997, 434, 383–391.
[142] Takakura Y, Morita T, Fujikawa M, Hayashi M, Sezaki H, Hashida M, Borchardt RT, Pharm. Res.
1995, 12, 1968–1972.
[143] Baer PC, Tunn UW, Nunez G, Scherberich JE, Geiger H, Exp. Nephrol. 1999, 7, 306–313.
[144] Janssen U, Phillips AO, Floege J, J. Nephrol. 1999, 12, 159–172.